Ently in progress will show more evidence of antitumor activity and that future studies combining signal transduction inhibitors, angiogenesis inhibitors, and nutrient depleting enzymes with each other and/or with traditional chemotherapeutic agents will bring out the effectiveness of these novel agents. floridalighttacklecharters.com/thq-buy-generic-viagra-online-cheap-tx/ cheap generic viagra buy viagra online buy cheap viagra cheap viagra online cheap generic viagra viagra online buy viagra viagra for sale cheap viagra online Future directions melanoma is strongly associated with inactivation of the retinoblastoma (rb) and p53 tumor suppressor pathways and activation of oncogenes in the ras cascade. Gene therapy to directly replace lost and/or mutated tumor suppressors at physiologic levels and in the appropriate tissue context remains a technical challenge, but it is a potential long-range scientific goal in the treatment of melanoma. Small-molecule human double minute 2 (hdm2) antagonists have been developed and have potential to treat tumors with wild-type tp53 (s13). B-raf and other ras pathway effectors are potential therapeutic targets in melanoma, and more potent b-raf–specific inhibitors may prove more effective than the general raf inhibitor bay 43-9006. There are efforts currently underway to target the pi3k ras-effector pathway with small-molecule inhibitors (s14). In addition, secondary analyses of trials designed to evaluate the effects of statins on coronary disease suggest that these agents may also have potential chemopreventive effects in melanoma (s15). One proposed mechanism of action of statins in melanoma prevention is blockade of prenylation, which is required for ras localization to the cell membrane (s16). Case-control studies and metaanalyses are ongoing to evaluate this preliminary observation. In addition to kinase pathways, other molecules unique to melanoma or melanocytes are viable drug targets. Although results of initial efforts using peptide and whole-cell extracts to stimulate an immune response to cell surface proteins specific to melanoma, including gm2, were promising, large-scale studies have not revealed significant antitumor activity (s17). However, efforts to enhance host response to cellular vaccines by augmenting tumor immunity, with agents such as recombinant gm-csf, may provide promising therapeutic agents ( 24 ). Since melanoma development is associated with telomerase activation (s18, s19), gene therapy approaches using anti-telomerase ribozymes (s20) and telomere homolog oligonucleotides (s21, s22) are currently in development for the treatment of melanoma and have shown antitumor activity in animal models. Targeting of pathways specific to melanocytes and critical to. high quality generic viagra